Background Over the past decade, cancer immunotherapies have revolutionized the treatment of melanoma; however, responses vary across patient populations. Recently, baseline tumor size has been identified as an independent prognostic factor for overall survival in patients with melanoma receiving immune checkpoint inhibitors. MG1 is a novel oncolytic agent with broad tumor tropism that has recently entered early-phase clinical trials. The aim of this study was to characterize T-cell responses in human and mouse melanoma models following MG1 treatment and to establish if features of the tumor immune microenvironment (TIME) at two distinct tumor burdens would impact the efficacy of oncolytic virotherapy. Methods Human three-dimensional in vitro priming assays were performed to measure antitumor and antiviral T-cell responses following MG1 infection. T-cell receptor (TCR) sequencing, T2 killing assay, and peptide recall assays were used to assess the evolution of the TCR repertoire, and measure specific T-cell responses, respectively. In vivo, subcutaneous 4434 melanomas were characterized using RNA sequencing, immunohistochemistry, and flow cytometry. The effectiveness of intratumoral MG1 was assessed in advancing 4434 tumors and the generation of antitumor and antiviral T cells measured by splenocyte recall assays. Finally, combination MG1 and programmed cell death protein-1 antibody (αPD-1) therapy was investigated in advanced 4434 tumors. Results MG1 effectively supported priming of functional cytotoxic T cells (CTLs) against tumor-associated antigens as well as virus-derived peptides, as assessed using peptide recall and T2 killing assays, respectively. TCR sequencing revealed that MG1-primed CTL comprised larger clusters of similar CDR3 amino acid sequences compared with controls. In vivo testing of MG1 demonstrated that MG1 monotherapy was highly effective at treating early disease, resulting in 90% cures; however, the efficacy of MG1 reduced as the disease burden (local tumor size) increased, and the addition of αPD-1 was required to overcome resistance in more advanced disease. Differential gene expression profiles revealed that increased tumor burden was associated with an immunologically colder TIME. Furthermore, analysis of TCR signaling in advancing tumors demonstrated a different dynamic of TCR engagement compared with smaller tumors, in particular a shift in antigen recognition by CD4+ cells, from conventional to regulatory subsets. Conclusion Addition of αPD-1 to MG1 is required to overcome viral therapy resistance in immunologically ‘colder’ more advanced melanoma, highlighting the importance of tumor burden to different types of immunotherapy.
PURPOSE: Comprehensive genomic profiling (CGP) using targeted panel next-generation sequencing (TP-NGS) is pivotal in the clinical management of advanced non–small cell lung cancer (aNSCLC). Despite the limitations associated with tumor tissue sampling, circulating tumor DNA (ctDNA) presents a promising alternative. This study aims to assess the prognostic value of ctDNA tumor fraction (TF) in aNSCLC. MATERIALS AND METHODS: We conducted a multicenter prospective study in Hong Kong. Patients with aNSCLC provided blood samples within 31 days before treatment initiation, followed by CGP using a validated ctDNA assay. RESULTS: Among 878 patients, those with ctDNA TF ≥1% had significantly worse outcomes, with median progression-free survival (PFS) of 13.2 months and overall survival (OS) of 17.6 months compared with the ctDNA TF <1% group ( P < .05). ctDNA TF demonstrated predictive capabilities for OS at various time points, with AUC values ranging from 0.65 to 0.75 for the overall population. The predictive strength of ctDNA TF in the epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor (TKI) subgroup remained robust for OS at 24 months, achieving an AUC of 0.79. We validated a ctDNA TF threshold of 2.3% for inferior OS in the overall population, whereas a distinct threshold of 1.6% and 2.2% was validated for EGFR TKI and chemotherapy ± immunotherapy. CONCLUSION: Our findings establish ctDNA TF as a clinically relevant biomarker in aNSCLC, providing robust prognostic and predictive information. The findings support the integration of ctDNA TF quantification into routine clinical workflows, reinforcing its role in advancing precision oncology and improving risk stratification and outcomes for patients with aNSCLC.
Prostate-specific antigen (PSA) is a well-established marker for prostate cancer screening, but current ≥4 ng/mL cutoff suffers from low specificity. This study aims to demonstrate the use of a long short-term memory (LSTM) network for accurate prediction of prostate cancer risk and next sequential PSA value. Hong Kong-wide PSA test data over a 25-year period, including PSA values, time difference between PSA tests, and PSA velocity change, were retrieved for model training with variable PSA cutoffs and sequence length. A total of 1,158,915 PSA tests from 499,342 patients (including 18,629 patients with prostate cancer) were included. Models predicting the next PSA level performed well (accuracy 0.724–0.910, AUROC 0.751–0.892). For a ≥4 ng/mL cutoff, the best model was at sequence length of 4 (AUROC 0.864). Temporal prediction of PSA performance was lower (accuracy 0.739–0.811, AUROC 0.740–0.849). Prostate cancer prediction performed excellent (AUROC 0.888–0.973), the sensitivity (0.734), and specificity (0.962) were high even at the shortest sequence length and a ≥4 ng/mL cutoff (4). Utilizing PSA levels only without additional markers or clinical data, LSTM-based models accurately predicted the next PSA level with modest temporal predictions while significantly improving the specificity of prostate cancer risk prediction, demonstrating their clinical utility.
16 September 2026 in Journal of the National Cancer Center
Long-term survivors of nasopharyngeal cancer (NPC) are at risk of excessive mortality. This territory-wide cohort study aims to investigate the relationship between statin use and mortality among 5-year survivors of NPC. This is a retrospective cohort study conducted with data from a territory-wide registry. Patients who survived five years after being diagnosed with non-metastatic NPC in Hong Kong between 1 January 1997 and 30 December 2015 were included. Patients were divided into statin users and statin non-users. We performed the inverse propensity of treatment weighting (IPTW) method to balance confounding factors. The primary outcome of overall survival (OS) was compared between the two groups and stratified by the cause of death, statin types and duration of statin usage. 7872 subjects (2439 statin users and 5433 statin non-users) were included in the final analysis. The 10-year, 15-year, and 20-year survival probabilities of statin users compared to non-users were 89.1 vs. 71.8%, 77.2 vs. 55.1%, and 59.2 vs. 42.4% respectively (HR 0.46, p < 0.001). After adjusting for immortal time bias, the hazard ratio for overall survival was 0.71 (p < 0.001). Statin use was associated with reduced risk of death due to secondary malignancy (HR 0.51; p = 0.002), cardiovascular disease (HR 0.64; p = 0.002), and pulmonary disease (HR 0.64; p = 0.011). Mortality was significantly lower in long-term statin usage of >6 years (HR 0.31; p < 0.001). In exploratory analyses, patients who received second- or third-generation statins were associated with a lower risk of mortality (HR 0.66 and HR 0.41, respectively), although this finding requires further validation. Our study suggests that statin usage is associated with reduced mortality in long-term NPC survivors. Further prospective study is warranted. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.